Literature DB >> 12095914

Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle.

Michael L Roberts1, Dominic J Wells, Ian R Graham, Stewart A Fabb, Vanessa J Hill, Ghislaine Duisit, Katsutoshi Yuasa, Shin'ichi Takeda, François-Loïc Cosset, George Dickson.   

Abstract

The ability to transfer the dystrophin gene stably to the skeletal muscle of DMD patients is a major confounding issue in establishing an effective gene therapy for this disease. To overcome this problem, we have examined the ability of muscle fibres from mdx mice to act as in situ factories of retroviral vector production. Tibialis anterior (TA) muscles from 4-week-old mdx mice were injected with an adenoviral vector expressing LacZ within a retroviral expression cassette (AdLZIN). Retroviral vector production was induced by the inclusion of two additional adenoviral vectors expressing retroviral gag-pol (AdGagPol) and 10A1 env genes (Ad10A1). Upon introduction of infected muscles into cell culture, colonies of beta-galactosidase-expressing myotubes formed only in cultures where the muscle was injected with AdLZIN, AdGagPol and Ad10A1, but not from muscle injected with AdLZIN only. Muscles from mdx/nude mice producing retroviral vector displayed a 4.6-fold increase in beta-galactosidase-positive myofibres after 1 month, compared with contralateral muscle in the same animal injected with AdLZIN and AdGagPol only. By constructing a hybrid adeno-retroviral vector expressing a truncated micro-dystrophin construct (AdmicroDyIN), we were able to partially correct the mdx dystrophic phenotype. AdmicroDyIN-mediated expression of micro-dystrophin in mdx TA muscle restored the formation of the dystrophin-associated glycoprotein complex and significantly reduced the level of muscle degeneration over uninjected controls. By stimulating in situ production of retroviral vector expressing micro-dystrophin, we achieved 92%+/-6% transduction of myofibres in the TA muscle by 4 weeks. Strikingly, by 3 months post injection, micro-dystrophin was still expressed to high levels in nearly all the myofibres of the TA muscle. By comparison, there was a pronounced drop in the levels of micro-dystrophin expressed by muscles injected with AdmicroDyIN only. Finally, using a novel PCR approach, we detected reverse-transcribed, integrated proviral sequences in TA muscle genomic DNA by 4 weeks post injection, the levels of which were found to increase after 3 months.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095914     DOI: 10.1093/hmg/11.15.1719

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  5 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

2.  Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression.

Authors:  En Kimura; Sheng Li; Paul Gregorevic; Brent M Fall; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2009-11-03       Impact factor: 11.454

3.  Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

Authors:  Kristy Swiderski; Scott A Shaffer; Byron Gallis; Guy L Odom; Andrea L Arnett; J Scott Edgar; Dale M Baum; Annabel Chee; Timur Naim; Paul Gregorevic; Kate T Murphy; James Moody; David R Goodlett; Gordon S Lynch; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2014-07-31       Impact factor: 6.150

4.  Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses.

Authors:  Judit Szécsi; Bertrand Boson; Per Johnsson; Pia Dupeyrot-Lacas; Mikhail Matrosovich; Hans-Dieter Klenk; David Klatzmann; Viktor Volchkov; François-Loïc Cosset
Journal:  Virol J       Date:  2006-09-03       Impact factor: 4.099

5.  Genome Editing Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Akitsu Hotta
Journal:  J Neuromuscul Dis       Date:  2015-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.